Anticoagulant, Antiplatelet, & Fibrinolytic Agents Drugs to Control Bleeding Clotting Disorders Thrombogenesis Normal body defense Becomes pathologic when causes vascular obstruction Section that breaks off and travels is known as an embolus Atherosclerosis Hemostasis Prevention or stoppage of blood loss from injured vessel (maintains vascular compartment integrity) Mechanisms involved: vasoconstriction Formation of platelet plug (clot lysis) Sequential activation of clotting factors Reparation of the opening in damaged vessel Atherosclerosis: Accumulation of lipid-filled macrophages (i.e., foam cells) on the inner lining of arteries Can affect any organ or tissue Often involves arteries supplying Heart (Thrombus may precipitate MI.) Brain (Thrombus may precipitate stroke.) Legs (Thrombus may precipitate DVT.) Status of blood, standing, PE is biggest risk Consequences and clinical implications depend on location and size of thrombi/emboli. Thrombotic and Thromboembolic Disorders Thrombosis may occur in arteries and veins. Arterial thrombosis Atherosclerotic plaque, HTN Turbulent blood flow Damage arterial endothelium and activate platelets to initiate coagulation Cause disease by blood flow obstruction Ischemia, infarction- CAN CAUSE IT ANYWHERE Antithrombotic and AntithromboembolicMedications Anticoagulants: Used in thrombotic disorders; DVT Prevention Primary prevention: Diet, exercise, or lifestyle modifications Secondary prevention: when you have a clot/plaquing, prevent further damage Antiplatelets: Used to prevent arterial thrombosis Thrombolytics: Dissolve thrombi and limit tissue damage in thromboembolic disorders They break down clots. Anticoagulant drugs Given to prevent new clot formation and extension of clots present Does not: dissolve formed clots, improve blood flow in tissues around the clot, or prevent ischemic damage beyond the clot Indications for use: prevention or management of thromboembolic disorders Thrombophlebitis, DVT, pulmonary embolism Main adverse effect: bleeding Anticoagulant Drugs; They work on veins Heparins Vitamin K antagonists Direct thrombin inhibitors (DTIs) Direct factor Xainhibitors Heparin LMWH –enoxaparin (Lovenox), dalteparin(Fragmin) Quick-acting; HIT* in 1-3% of patients after 4-14 days; HIT (heparin induced thrombocytopenia) IV or Subcutaneous (not absorbed in GI tract) NOT removed in hemodialysis Does NOT cross placenta*** & NOT in breast milk*** Used prophylactically (prevent DVT & PE) Major surgery or illness Immobility Used therapeutically to prevent further thromb/emb DVT, PE, thrombophlebitis Disseminated intravascular coagulation (DIC); Too much clotting that puts you at risk of bleeding. Uses the clotting factor and the rest of blood can not clot. Heparin interferes with the clotting long enough for your body to produce more clotting factor, and the body stabilizes. Vitamin K antagonists Warfarin (Coumadin) –most common; Overlaps with heparin treatment Prevents synthesis of vitamin K-dependent clotting factors NO IMPACT on existing clotting factors; (so it takes 3-5 days for it to begin working) Long-term mgmt. of DVT, PE, AF, Prosthetic heart valve Attention to dietary vitamin K; Maintain Vitamin K intake; Know dietary sources of Vit. K Direct thrombin inhibitors (DTIs) Dabigatran (Pradaxa), argatroban, bivalirudin, desirudin Interferes with the effect of thrombin on fibrinogen Benefits: Acts on BOTH circulating & clot-bound thrombin AND has antiplatelet activity More predictable response to med; no drug monitoring required Less incidence of immune-mediated thrombocytopenia (ITP) Antidote - idarucizumab(Praxbind) –bleeding, emergent surgery Beers List***; Caution with renal impairment Use: stroke prevention with NONVALVULAR AF; Treatment/Prevention of DVT & PE If used with valvular AF, risk of bleeding Direct factor Xainhibitors Rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban Inhibits thrombin production by inactivating (circulating & clot-bound) factor Xa Less life-threatening bleeding than warfarin Use: Treatment of secondary and Prevention of VTE and stroke with NONVALVULAR AF Beers List*** Unsafe during pregnancy (bleeding & fetal risk) No drug monitoring required Anticoagulant Management Heparin: regulated by activated partial thromboplastin time (aPTT) Lab drawn approximately equal to 1 hour before dosing Warfarin: regulated by international normalized ratio (INR), based on prothrombin time (PT) Lab drawn daily until therapeutic Therapeutic = 1.5; Hold > 3 Once therapeutic, drawn every 2 to 4 weeks for duration of anticoagulant therapy, unless dose adjusted Antiplatelet Drugs Prevent one or more steps in prothrombotic activity of platelets Act by a variety of mechanisms Inhibit platelet activation Inhibit platelet adhesion Inhibit platelet aggregation Inhibit procoagulant activity Adverse effects depend on the medication used. Antiplatelet Drugs; They work on arteries Adenosine diphosphate receptor antagonists Thromboxane A2 inhibitors Glycoprotein IIb/IIIa receptor antagonists Phosphodiesterase-3 enzyme inhibitor Adenosine diphosphate receptor antagonists clopidogrel (Plavix), prasugrel, ticagrelor, cangrelor Blocks ADP receptor on platelet cell surface Cons: Blocking action is irreversible(no antidote), permanent action; Platelet transfusion if something goes wrong Delayed onset of action Significant variability in platelet response Use: Prevention of stroke, MI, vascular ischemia in ACS, AF (in patients who cannot take warfarin), after stent (with ASA) Caution with hepatic impairment, pregnancy, lactation Thromboxane A2 inhibitors 1/2 acetylsalicylic acid (Aspirin) Inhibits synthesis of prostaglandins and prevents thrombus formation Irreversible –lasts the life of the platelet (no antidote) Use: Prevention of MI, stroke, heart valve pts; Treatment of MI, TIA,evolving thrombotic strokes Main S/E: risk of bleeding Thromboxane A2 inhibitors 2/2 NSAIDs -ibuprofen Inhibits synthesis of prostaglandins and prevents thrombus formation Reversible –effect on platelet stops when drug removed Not typically used as antiplatelet, but if patient takes ibuprofen daily, they may not need additional ASA *Tylenol usually does not affect platelets Glycoprotein IIb/IIIa receptor antagonists abciximab(ReoPro) –monoclonal antibody that prevents the binding of fibrinogen, von Willebrand factor to GPIIb/IIIa platelet receptors, thus inhibiting platelet aggregation eptifibatide (Integrilin), tirofiban (Aggrastat) –same action Use: Prevention of thrombosis of arteries after PTCA or atherectomy Action stops when drug stopped Contraindications: h/o stroke, bleed, surgery or trauma in past 30 days; h/o aneurysm, av malformation, ICH ever Phosphodiesterase-3 enzyme inhibitor Cilostazol (Pletal) –used for intermittent claudication Takes 2-12 weeks to work Inhibits phosphodiesterase, which inhibits platelet aggregation and produces vasodilation BLACK BOX WARNING: Not for use in patients with HF Anagrelide –used for essential thrombocythemia (Too many platelets) Dipyridamole –used in combination (Aspirin/Warfarin) for heart valve replacement and Prevention of stroke Thrombolytic Agents; Clot Buster Given to dissolve thrombi Usually stroke patients, and we must know there normal, work best on newer clots Stimulate conversion of plasminogen to plasmin (enzyme that breaks down fibrin) Management of acute, severe thromboembolic disease MI, PE, iliofemoral thrombosis Goal: reestablish blood flow as quickly as possible, prevent/limit tissue damage Main adverse effect: bleeding Thrombolytic Therapy Recombinant tissue plasminogen activators (rtPA) alteplase (Activase), Tenecteplase (TNKase) Performed only by experienced personnel in ICU or diagnostic/interventional setting with cardiac monitoring in place Baseline laboratories (INR, aPTT, platelet count, fibrinogen) needed preadministration Factors in bleeding decrease include: careful selection of recipients, avoiding invasive procedures, omitting anticoagulants or antiplatelets during use. Use in Special Populations Children, Older adults, Renal impairment, Hepatic impairment, Home care, Herbal and dietary supplement use Monitor for accumulation effect, make sure they are excreting the medications Nurse Considerations: Monitor for bleeding and patient education; Medical jewelry Take medication at the same time, each day. Be more conscious when performing activities. Drugs Used to Control Bleeding (Antidotes) Warfarin → vitamin K (Mephyton) Warfarin (urgent) → PT complex (Kcentra) Heparin → protamine sulfate Dabigatran → idarucizumab(Praxbind) tPA → aminocaproic acid (Amicar) Thrombolytics → tranexamic acid (TXA)